The World Health Organization has warned that antibiotic resistant
"superbugs" may give rise to a global health emergency. Already about
7000 Australians die annually from infections caused by drug-resistant
bacteria, but pharmaceutical companies seem reluctant to produce new
medicines to tackle the problem. Long lead times for drug development,
commercial risks and government policies that keep costs down are among
the reasons why big pharma is intent on treating diseases and conditions
that keep patients coming back for more. A national surveillance
program is urgently needed. Meanwhile, strategies devised at an
interdisciplinary summit at the University of New South Wales aim to